Drug‐Induced Skin Lesions of Bilateral Lower Extremities in an Elderly Patient With Poorly Controlled Diabetes Authors: Jie Chen, Hua Wang, Linxuan Gu, Xiwen Zhu, Bangtao Yao Published: 2026 ABSTRACT ABSTRACTThis study described a rare case of an 83‐year‐old man diagnosed with drug‐induced skin lesions of bilateral lower extremities after continuous self‐administration with clobetasol propionate ointment for eczema. On admission, his skin was paper‐thin, peeling, dry, bruising, and swollen on both lower extremities. Topical clobetasol propionate was immediately discontinued. During a 2‐week follow‐up period, his symptoms had resolved significantly.Keywords: drug‐induced skin lesions, eczema, high‐potency corticosteroids, treatment Case Presentation An 83‐year‐old man with poorly controlled diabetes presented with a 2‐week history of swelling and pain on both lower extremities. He had received a diagnosis of eczema on both lower extremities, and continuous self‐administration with clobetasol propionate ointment (doses, 5 g daily) for 10 days, but he had developed swelling and pain. 3 days later, his symptoms progressively worsened. On admission, the vital signs were normal. His skin was paper‐thin, peeling, dry, bruising, and swollen on both lower extremities (Figure 1). On magnified photograph, several ulcers were observed (Figure 2). His fasting blood glucose was 14.0 mmol/L (reference, 3.9 to 6.1), glycosylated hemoglobin was 13.3% (reference, 4.0 to 6.9), leucocyte counts were 12.87 × 109/L (reference, 0 to 8), C‐reactive protein was 45.76 mg/L (reference, 0.5 to 10). Other investigations showed unremarkable. The paper‐thin, peeling, dry, bruising, and swollen skin was visible on both lower extremities. On magnified photograph, several ulcers were observed. A score of 5 was evaluated using the Naranjo Adverse Drug Reaction Probability Scale, which was categorized as “probable”. A diagnosis of drug‐induced skin lesions of bilateral lower extremities was made. However, the patient refused to undergo vascular assessments (pulses, doppler ultrasound), surgical consultation, blood cultures, or skin biopsy. Topical clobetasol propionate was immediately discontinued. Anti‐infective treatment and skin wound care for both legs were performed. During a 2‐week follow‐up period, his symptoms had resolved significantly. Discussion Corticosteroids are widely used by general physicians. For mild and moderate eczema, topical corticosteroids is considered the first‐line treatment, reducing inflammation and regulating immune system activity [1, 2]. Clobetasol propionate (a high‐potency corticosteroid) is effective for diverse skin diseases, such as eczema and psoriasis [2]. However, local adverse effects (e.g., telangiectasia, hypopigmentation, ulcer) and systemic complications (e.g., Cushing syndrome and intracranial hypertension) following its inappropriate use, are described [2]. The occurrence of these consequences is notably higher after long‐term use or when the cumulative dosage exceeds 32 g in the general population [3]. High‐potency topical corticosteroids primarily cause skin atrophy, barrier disruption, impaired wound healing, and secondary infection, rather than direct necrosis [3]. The Naranjo Adverse Drug Reaction Probability Scale was not designed for topical agents or delayed cutaneous toxicity, however, it may be useful for evaluating clinical causality assessment. In this case, skin lesions (e.g., necrosis) likely represented a multifactorial process, potentially involving: steroid‐induced epidermal and dermal atrophy, impaired local immunity, mechanical fragility, diabetic microangiopathy, and secondary infection or ischemia. Once the diagnosis of drug‐induced effects is established, discontinuing medication is essential. Otherwise, patients will lead to serious complications and poor clinical prognosis. Furthermore, calcineurin inhibitors are alternative treatments in patients with diabetes, offering safer options [2]. Besides, rehabilitation advice may be beneficial for improvement of the condition. Author Contributions Jie Chen: investigation, writing – original draft. Linxuan Gu: supervision. Xiwen Zhu: writing – review and editing. Bangtao Yao: investigation, writing – review and editing. Hua Wang: writing – review and editing. Funding The authors have nothing to report. Ethics Statement The study was approved by the Institutional Review Board of Nanjing Lishui People's Hospital. Consent Written informed consent was obtained from patient to publish this report in accordance with the journal's patient consent policy. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Contributor Information Xiwen Zhu, Email: zxw2359@163.com. Bangtao Yao, Email: yaobamtao_njmu@163.com. Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.